T.R. Leyshon Griffiths

Author

Also Known As

A M McDonald, Griffiths, Griffiths, Thomas L., L Griffiths, L. Griffiths, Lampinen, Andrew K., Leroy Griffiths, Leyshon Griffiths, Sam McClinton, T Griffiths

124

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Freeman Hospital Newcastle University University Hospitals of Leicester NHS Trust Leicester General Hospital University of Leicester

About

T.R. Leyshon Griffiths is an author at Freeman Hospital specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	651
2	Cell Biology	5	5	254
3	Pathology	5	5	190
4	Engineering	1	1	29
5	Pharmacology	1	1	42

T.R. Leyshon Griffiths

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer Emre Sayan, T.R. Leyshon Griffiths, Raj P. Pal, Proceedings of the National Academy of Sciences	2009	189
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial Wei Shen Tan, Anesh Panchal, Laura Buckley, European Urology Urological ResearchUrologySurgical OncologyGenitourinary CancerMedicine	2018	137
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence T.R. Leyshon Griffiths, I. Brotherick, RI Bishop, British Journal of Cancer UrologyGenitourinary CancerMedicineCell AdhesionCell Adhesion Molecules	1996	98
Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment Andreas Skolarikos, T.R. Leyshon Griffiths, Philip Powell, Urology Cytologic AnalysisUrological ResearchUrologyVoiding DysfunctionUpper Tract Tcc	2003	84
Treatment of Carcinoma In Situ With Intravesical Bacillus Calmette-Guerin Without Maintenance T.R. Leyshon Griffiths, Mary E. Charlton, David E. Neal, The Journal of Urology	2002	80
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis Rana Abdel‐Fattah, Christine Challen, T.R. Leyshon Griffiths, British Journal of Cancer Tp53 AccumulationTumor BiologyUrologyGenitourinary CancerMedicine	1998	60
Combined Treatment of Bladder Cancer Cell Lines with Lapatinib and Varying Chemotherapy Regimens—Evidence of Schedule-Dependent Synergy Lynsey A. McHugh, Marina Kriajevska, J. Kilian Mellon, Urology Schedule-dependent SynergyUrologyGenitourinary CancerMedicineCancer Cell Biology	2007	54
Prognostic markers in bladder cancer T.R. Leyshon Griffiths, David E. Neal Current Opinion in Urology Prognostic BiomarkersUrologyUrological ResearchGenitourinary CancerMedicine	1996	49
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer Hugh Mostafid, Núria Porta, Joanne Cresswell, British Journal of Urology	2020	44
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial Chris Parker, Noel W. Clarke, Adrian Cook, The Lancet	2024	43

Page 1